HYPERLAB
High yield and performance stem cell lab
| Coordinatore | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙907˙456 € |
| EC contributo | 2˙987˙601 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-FP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-09-01 - 2012-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | coordinator | 409˙610.47 |
| 2 |
KLINIKUM DER UNIVERSITAET ZU KOELN
Organization address
address: Kerpener Strasse 62 contact info |
DE (KOELN) | participant | 460˙182.00 |
| 3 |
Nome Ente NON disponibile
Organization address
address: Rosenhof 1 contact info |
DE (Heilbad Heiligenstadt) | participant | 432˙644.00 |
| 4 |
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA
Organization address
address: Av. da Republica, Quinta do Marques S/N contact info |
PT (OEIRAS) | participant | 400˙200.00 |
| 5 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 397˙245.00 |
| 6 |
TAKARA BIO EUROPE AB
Organization address
address: ARVID WALLGRENS BACKE 20 contact info |
SE (GOETEBORG) | participant | 362˙575.00 |
| 7 |
ARTTIC
Organization address
address: Rue du Dessous des Berges 58A contact info |
FR (PARIS) | participant | 221˙046.00 |
| 8 |
CRYO-SAVE GROUP NV
Organization address
address: IJsselkade 8 contact info |
NL (Zutphen) | participant | 202˙722.53 |
| 9 |
UNIVERSIDAD CATOLICA DEL NORTE
Organization address
address: AVENIDA ANGAMOS 0610 contact info |
CL (ANTOFAGASTA) | participant | 101˙376.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The success of stem cell therapy is highly dependent on a safe and reliable supply of human stem cells and stem cell-derived differentiated cells, which must be assured by efficient and robust culture methods. Current culture of human embryonic and adult stem cells is not optimised (with regards to e.g. media, growth factors, supporting biomaterials, differentiation techniques) and is far from fulfilling the demands in terms of reproducibility and preciseness. Additionally, current methods do not allow fast screening of culture conditions for their systematic optimisation. These limitations currently slow down the development of stem cell applications and will be addressed and overcome by the Hyperlab project. To reach the overall aim of developing new and improved culture methods, media and protocols for stem cell cultivation and differentiation, Hyperlab will adapt novel microfluidics-based cell cultivation technologies to the specific needs of stem cell culture. The developed culture systems will have two major advantages over existing approaches: on the one hand, they will improve stem cell culture in terms of microenvironment control, reproducibility, robustness and efficiency. On the other hand, these microscale technologies, together with developed transgenic readout systems, will allow medium to high throughput screening of culture conditions, enabling determination of optimal protocols in shorter time. Once established, technologies, protocols and conditions will be evaluated for their upscalability and will be made GMP-compliant to form a solid basis for progress in human stem cell therapy. To implement this innovative strategy, Hyperlab follows an integrated approach, bringing together renowned experts from stem cell biology, microsystem technologies, biomaterial design and relevant regulatory bodies. Hyperlab is thus in a position to provide standardised, reproducible methods and tools to advance therapeutic stem cell research.'
Introduzione (Teaser)
Stem cell-based therapies depend on robust supply of stem cells of adequate quality. The EU-funded HYPERLAB project developed new technologies for improved cultivation and differentiation of human stem cells.